1. Amenorrhea rates in women treated with novel oral, continuous hormonal therapy of body identical 17β-estradiol and micronized progesterone. (October 2021) Authors: Pickar, James H.; Archer, David F.; Graham, Shelli; Zablotna, Renata; Boolell, Mitra; Mirkin, Sebastian Journal: Maturitas Issue: Volume 152(2021) Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Novel oral combined 17β-estradiol (E2) and micronized progesterone (P4) therapy improves vasomotor symptoms (VMS) and sleep in postmenopausal women (PW). (October 2021) Authors: Pickar, James H.; Graham, Shelli; Zablotna, Renata; Boolell, Mitra; Mirkin, Sebastian Journal: Maturitas Issue: Volume 152(2021) Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice. (June 2023) Authors: Panay, Nick; Nappi, Rossella E.; Stute, Petra; Palacios, Santiago; Paszkowski, Tomasz; Kagan, Risa; Archer, David F.; Héroux, Julie; Boolell, Mitra Journal: Maturitas Issue: Volume 172(2023) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗